CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Vir Biotechnology, Inc.

VIR
$1.85BSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for VIR. That does not mean none is planned.

Get an email about VIR's next catalysts

Track Vir Biotechnology (VIR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Catalyst Timeline

1 upcoming, 4 past

Phase 3
βœ“Positive

Tobevibart Phase 3 Est. Readout

December 2026~Tobevibart150

Estimated primary completion for Tobevibart trial (NCT07128550) in Viral Hepatitis. Topline data typically follows completion by weeks to months.

44% of patients who received once-monthly tobevibart and (combination partner truncated in article) achieved the study's response endpoint; first of three late-stage studies to succeed.

Source

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)πŸ‡ΊπŸ‡ΈNorth AmericaSAN FRANCISCO408 employees
Drug Pipeline

Frequently asked questions

What is in Vir Biotechnology, Inc.'s drug pipeline?β†’

CatalystAlert tracks 17 drug candidates in Vir Biotechnology, Inc.'s (VIR) pipeline across Phase 3, Phase 2. Its lead program is Tobevibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Vir Biotechnology, Inc.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for Vir Biotechnology, Inc. (VIR) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track VIR biotech catalysts?β†’

Add VIR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vir Biotechnology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply